ARCA biopharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ARCA biopharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	23.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ARCA biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:ABIO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	N/A	-6	-5	-5	N/A
12/31/2023	N/A	-5	-5	-5	N/A
9/30/2023	N/A	-5	-5	-5	N/A
6/30/2023	N/A	-6	-6	-6	N/A
3/31/2023	N/A	-8	-8	-8	N/A
12/31/2022	N/A	-10	-11	-11	N/A
9/30/2022	N/A	-14	-14	-14	N/A
6/30/2022	N/A	-17	-17	-17	N/A
3/31/2022	N/A	-18	-18	-18	N/A
12/31/2021	N/A	-19	-19	-19	N/A
9/30/2021	N/A	-19	-17	-17	N/A
6/30/2021	N/A	-16	-14	-14	N/A
3/31/2021	N/A	-13	-11	-11	N/A
12/31/2020	N/A	-10	-8	-8	N/A
9/30/2020	N/A	-6	-6	-6	N/A
6/30/2020	N/A	-5	-5	-5	N/A
3/31/2020	N/A	-5	-5	-5	N/A
12/31/2019	N/A	-5	-5	-5	N/A
9/30/2019	N/A	-6	-5	-5	N/A
6/30/2019	N/A	-6	-6	-6	N/A
3/31/2019	N/A	-7	-7	-7	N/A
12/31/2018	N/A	-8	-8	-8	N/A
9/30/2018	N/A	-11	-11	-11	N/A
6/30/2018	N/A	-13	-13	-13	N/A
3/31/2018	N/A	-17	-16	-16	N/A
12/31/2017	N/A	-18	N/A	-17	N/A
9/30/2017	N/A	-19	N/A	-17	N/A
6/30/2017	N/A	-19	N/A	-17	N/A
3/31/2017	N/A	-17	N/A	-15	N/A
12/31/2016	N/A	-16	N/A	-15	N/A
9/30/2016	N/A	-15	N/A	-14	N/A
6/30/2016	N/A	-14	N/A	-12	N/A
3/31/2016	N/A	-12	N/A	-11	N/A
12/31/2015	N/A	-11	N/A	-11	N/A
9/30/2015	N/A	-11	N/A	-10	N/A
6/30/2015	N/A	-10	N/A	-9	N/A
3/31/2015	N/A	-10	N/A	-9	N/A
12/31/2014	N/A	-10	N/A	-9	N/A
9/30/2014	N/A	-10	N/A	-9	N/A
6/30/2014	N/A	-9	N/A	-9	N/A
3/31/2014	N/A	-10	N/A	-8	N/A
12/31/2013	N/A	-9	N/A	-5	N/A
9/30/2013	N/A	-7	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ABIO's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if ABIO's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ABIO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ABIO's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ABIO's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ABIO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ARCA biopharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) for approximately $180 million in a reverse merger transaction.

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) in a reverse merger transaction.

New major risk - Share price stability

Arca Biopharma, Inc. Announces Executive Changes

ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024

ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General Counsel

ARCA biopharma, Inc. Appoints James Flynn to Board of Directors

Insufficient new directors

ARCA biopharma, Inc., Annual General Meeting, Dec 15, 2022

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA Biopharma, Inc. Appoints Jacob Ma-Weaver Has Joined Its Board of Directors

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

Insufficient new directors

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma, Inc. Announces Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma, Inc. Announces Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Senior VP recently bought US$113k worth of stock

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

ARCA biopharma, Inc. Provides Update on Aspen-Covid-19 Phase 2B Clinical Trial

Chief Accounting Officer & VP of Finance has left the company

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

New 90-day low: US$3.98

New 90-day high: US$4.93

New 90-day high: US$4.55

ARCA biopharma, Inc. Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA biopharma, Inc. Announces AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

New 90-day low: US$3.81

ARCA biopharma reports Q3 results

New 90-day low: US$4.03

ARCA biopharma, Inc. Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

ARCA biopharma, Inc. Announces Promotion of Debra Marshall to Chief Medical Officer

New 90-day low: US$4.18

ARCA biopharma, Inc. Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

New 90-day low - US$5.34

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies